Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.242826
Abstract: Recent clinical data have shown a synergistic effect of venetoclax in combination with the hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with incomplete cell count recovery [CRi]: 73%, median overall survival [OS] of… read more here.
Keywords: low dose; combination hypomethylating; myeloid leukemia; dose cytarabine ... See more keywords